Bone Biologics (NASDAQ:BBLG) vs. Nexien Biopharma (OTCMKTS:NXEN) Financial Contrast

Bone Biologics (NASDAQ:BBLG) and Nexien Biopharma (OTCMKTS:NXEN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Bone Biologics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Nexien Biopharma has a beta of -0.94, meaning that its share price is 194% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Bone Biologics and Nexien Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1	0	0	0	1.00
Nexien Biopharma	0	0	0	0	0.00

Given Nexien Biopharma’s higher probable upside, analysts clearly believe Nexien Biopharma is more favorable than Bone Biologics.

Profitability

This table compares Bone Biologics and Nexien Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
Nexien Biopharma	N/A	N/A	N/A

Valuation and Earnings

This table compares Bone Biologics and Nexien Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11 million	($2.27)	-0.58
Nexien Biopharma	N/A	N/A	-$240,000.00	N/A	N/A

Institutional and Insider Ownership

34.3% of Bone Biologics shares are held by institutional investors. 6.1% of Bone Biologics shares are held by company insiders. Comparatively, 30.6% of Nexien Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Nexien Biopharma beats Bone Biologics on 5 of the 8 factors compared between the two stocks.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

About Nexien Biopharma

Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.